Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06360627

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Radiation Exposure Cardiovascular Diseases Embolism Embolism and Thrombosis Infections Lung Cancer Lung Diseases Lung Embolism Lung Neoplasms Neoplasms Neoplasms by Site Pneumonia Pulmonary Embolism Respiratory Tract Diseases Respiratory Tract Infections Respiratory Tract Neoplasms Thoracic Neoplasms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CT SCAN for pulmonary nodule detection/follow up
  • CT SCAN for pneumonia detection/follow up

Exclusion criteria

  • under 18
  • BMI over 30

Treatment and study plan

computed tomography

Radiation

Computed Tomography CHEST

Primary outcomes

  1. Dose Reduction by new scanner

    Time frame: through study completion, an average of 1 year

    mSv per exam will be recorded. This value will be put in correlation to weight (Kg), height (cm) and BMI.

  2. stable Image Quality in reduced dose scans

    Time frame: through study completion, an average of 1 year

    Recorded values compared in 2 populations-different contrast agents by using qualitative&quantitative methods Qualitative:diagnostic certainty, assessability of lung structure/lesions,diagnostic reliability,

    Quantitative:Assessment of tissue composition,diagnostic performance measurements Attenuation/sealing measurement (HU), signal-to-noise ratio (SNR), contrast-to-noise ratio ,size dimensions of lung structure/lesion in three dimensions in millimeters Tissue composition assessment diagnostic performance measurements (sensitivity, specificity, accuracy) diagnostic confidence: 1-4

    Theses measurements will be put in correlation to the scan dose (mSv) per patient, forming two groups with matched BMI (kg/m^2)

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Apr 11, 2024
Registry last updated
Apr 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.